Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for soft-tissue sarcomas

A D Elias1

  • 1Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Clinical Orthopaedics and Related Research
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

European journal of cancer (Oxford, England : 1990)·2013
Same author

High dose chemotherapy with stem cell rescue for breast cancer: current status and future directions.

Breast disease·2005
Same author

The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2002
Same author

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.

Bone marrow transplantation·2001
Same author

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.

Bone marrow transplantation·2001
Same journal

Impact Microindentation Evaluates Bone Strength, Bone Quality, and Fracture Susceptibility Across Skeletal Sites: A Cadaver Study.

Clinical orthopaedics and related research·2026
Same journal

What Is the Effect of Robot Reduction in Displaced Pelvic Fractures? A Multicenter Randomized Clinical Trial.

Clinical orthopaedics and related research·2026
Same journal

CORR Insights®: Acute or Delayed TKA for Tibial Plateau Fracture? An Observational Study From the Swedish Arthroplasty Register.

Clinical orthopaedics and related research·2026
Same journal

Reply to the Letter to the Editor: Guest Editorial: Recalling a Recall.

Clinical orthopaedics and related research·2026
Same journal

Radial Head Fractures Cluster in the Anterolateral and Anteromedial Quadrants and Do Not Correlate With Coronoid Fracture Types.

Clinical orthopaedics and related research·2026
Same journal

Reduced Cerebellar Activation With Eyes Closed Is Associated With Delayed Peroneal Reaction Time in Patients With Chronic Ankle Instability.

Clinical orthopaedics and related research·2026
See all related articles

Doxorubicin and ifosfamide chemotherapy show over 20% activity. While combination therapies increase response rates and toxicity, they do not improve survival compared to single-agent doxorubicin.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Single-agent chemotherapy, including doxorubicin and ifosfamide, demonstrates over 20% activity.
  • Anthracycline analogues exhibit similar efficacy.
  • The comparative benefit of combination chemotherapy versus single-agent doxorubicin remains under investigation.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of combination chemotherapy compared to single-agent doxorubicin.
  • To assess the role of adjuvant chemotherapy in improving survival outcomes.
  • To identify the need for novel therapeutic strategies to overcome drug resistance.

Main Methods:

  • Review of randomized clinical trials comparing single-agent and combination chemotherapy regimens.
  • Analysis of response rates, toxicity profiles, and survival data.

Related Experiment Videos

  • Evaluation of data regarding the use and effectiveness of adjuvant chemotherapy.

    • Main Results:

    • Combination therapies show enhanced response rates but also increased toxicity compared to single-agent doxorubicin.
    • Limited follow-up data indicate no significant improvement in overall survival with combination therapies.
    • Adjuvant chemotherapy's role is not definitively established, with some trials showing survival benefits but most indicating only a delay in relapse.
    • A notable risk of irreversible toxicity exists with current combination regimens.

    Conclusions:

    • Current combination chemotherapy regimens offer limited survival advantage over single-agent doxorubicin despite higher response rates and toxicity.
    • Further research is essential to develop new agents, targets, and strategies to overcome chemotherapy resistance.
    • Novel approaches are required to improve long-term outcomes in patients undergoing chemotherapy.